Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Current Leases (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Current Leases for 5 consecutive years, with $2.4 million as the latest value for Q4 2025.

  • Quarterly Current Leases rose 36.82% to $2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.4 million through Dec 2025, up 36.82% year-over-year, with the annual reading at $2.4 million for FY2025, 36.82% up from the prior year.
  • Current Leases for Q4 2025 was $2.4 million at Janux Therapeutics, up from $2.3 million in the prior quarter.
  • The five-year high for Current Leases was $2.4 million in Q4 2025, with the low at $88000.0 in Q2 2022.
  • Average Current Leases over 5 years is $1.3 million, with a median of $1.5 million recorded in 2023.
  • The sharpest move saw Current Leases skyrocketed 1500.0% in 2023, then rose 14.91% in 2025.
  • Over 5 years, Current Leases stood at $194000.0 in 2021, then surged by 293.3% to $763000.0 in 2022, then soared by 98.82% to $1.5 million in 2023, then grew by 15.29% to $1.7 million in 2024, then soared by 36.82% to $2.4 million in 2025.
  • According to Business Quant data, Current Leases over the past three periods came in at $2.4 million, $2.3 million, and $1.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.